Hari Hendarto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hari Hendarto has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Femmy Nurul Akbar
Department of Internal Medicine, Faculty of Medicine, Syarif Hidayatullah State Islamic University (UIN) Jakarta
4 shared publications - Hadianti Adlani
Universitas Islam Negeri Syarif Hidayatullah
2 shared publications Efriadi Ismail
Department of Pulmonology, The National COVID-19 Emergency Hospital Wisma Atlet Kemayoran Jakarta 10620, Indonesia
1 shared publication- Endah Wulandari
Department of Biochemistry, Histology, Clinical Nutrition, Bioethics and Physiology, Faculty of Medicine, SyarifHidyatullah Jakarta, State Islamic University, Ciputat, 15419, Indonesia
1 shared publication Hilman Tadjoedin
Department of Internal Medicine-Haematology-Oncology Division, Dharmais Cancer Hospital Jakarta Jakarta,11420, Indonesia
1 shared publication- Hoirun Nisa
Department of Public Health, Faculty of Health Sciences, Syarif Hidayatullah State Islamic University (UIN) Jakarta
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Indonesian Public Health Association in Public Health of Indonesia
- Vol. 12 (3) , 54-63
Prevalence and patterns of chronic non-communicable disease multimorbidity in an Indonesian adult population
Background: Chronic non-communicable diseases (NCDs) are a global health challenge, with increasing prevalence of multimorbidity. Objective: This study was to examine the prevalence of chronic NCDs and their multimorbidity patterns in the Indonesian adult population. Methods: Data were extracted from the Indonesian Family Life Survey wave 5 (IFLS-5) and included 17,958 participants aged at least 35 years. Information on 14 chronic NCDs was self-reported to estimate the prevalence of chronic NCDs and multimorbidity. Descriptive statistics were employed to explore the patterns of chronic NCDs multimorbidity, and chi-square tests were used to examine the relationships of age and gender with chronic NCDs multimorbidity. Results: Of all participants, 4,537 (25.3%) participants had one chronic NCD, and 2,749 (15.3%) participants had chronic NCDs multimorbidity. The chronic NCD multimorbidity prevalence increased with advancing age, from 8.6% in individuals age 35-44 years to 25.0% age 65-74 years. Women had a significantly higher multimorbidity of chronic NCDs compared to men. Hypertension (19.1%) was the most prevalent NCDs and appeared in various multimorbidity patterns. The most prevalent of a two-disease combination was hypertension and arthritis, and the most prevalent of a three-disease combination was hypertension, arthritis, and stomach or digestive diseases. Conclusion: The prevalence of chronic NCDs and their multimorbidity is quite high in Indonesian adults, with a complex pattern of multimorbidity. Hypertension occurs in various patterns of multimorbidity. These findings add to the importance of health management and clinical guidelines that focus not only on one chronic NCD but also on various chronic NCD multimorbidity conditions in Indonesian adults. Keywords. Chronic diseases; NCDs; Multimorbidity; Adult, Indonesia
- 15 September 2026
- Published by Indonesian Public Health Association in Public Health of Indonesia
- Vol. 12 (3) , 54-63
Open AccessPrevalence and patterns of chronic non-communicable disease multimorbidity in an Indonesian adult population
Background: Chronic non-communicable diseases (NCDs) are a global health challenge, with increasing prevalence of multimorbidity. Objective: This study was to examine the prevalence of chronic NCDs and their multimorbidity patterns in the Indonesian adult population. Methods: Data were extracted from the Indonesian Family Life Survey wave 5 (IFLS-5) and included 17,958 participants aged at least 35 years. Information on 14 chronic NCDs was self-reported to estimate the prevalence of chronic NCDs and multimorbidity. Descriptive statistics were employed to explore the patterns of chronic NCDs multimorbidity, and chi-square tests were used to examine the relationships of age and gender with chronic NCDs multimorbidity. Results: Of all participants, 4,537 (25.3%) participants had one chronic NCD, and 2,749 (15.3%) participants had chronic NCDs multimorbidity. The chronic NCD multimorbidity prevalence increased with advancing age, from 8.6% in individuals age 35-44 years to 25.0% age 65-74 years. Women had a significantly higher multimorbidity of chronic NCDs compared to men. Hypertension (19.1%) was the most prevalent NCDs and appeared in various multimorbidity patterns. The most prevalent of a two-disease combination was hypertension and arthritis, and the most prevalent of a three-disease combination was hypertension, arthritis, and stomach or digestive diseases. Conclusion: The prevalence of chronic NCDs and their multimorbidity is quite high in Indonesian adults, with a complex pattern of multimorbidity. Hypertension occurs in various patterns of multimorbidity. These findings add to the importance of health management and clinical guidelines that focus not only on one chronic NCD but also on various chronic NCD multimorbidity conditions in Indonesian adults. Keywords. Chronic diseases; NCDs; Multimorbidity; Adult, Indonesia
- Open Access
- 29 July 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (07) , 1002-1009
Efficacy of therapeutic-dose heparin for severe COVID-19 patients at COVID-19 Emergency Hospital Jakarta
Introduction: Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality. For optimal thromboprophylaxis treatment for hospitalized patients, especially those with severe COVID-19 symptoms, it is still unclear whether to use full- or therapeutic-dose versus prophylactic-dose anticoagulation therapy. The study aim was to evaluate the efficacy and safety of unfractionated heparin (UFH) for thromboprophylaxis in severe degree of COVID-19. Methodology: In this cross-sectional study, the medical records of 160 COVID-19 patients at the COVID-19 Emergency Hospital Wisma Atlet, Jakarta, from March to August 2021, were collected. The predetermined inclusion criteria for patients were severe COVID-19 infection; age > 18 years; positive D-dimer level > 400 ng/mL; high-flow nasal cannula (HFNC) oxygenation; IMPROVE bleeding risk score < 7; and willingness to participate in the study. The primary outcome was activated partial thromboplastin time (APTT) target achievement, oxygenation changed to nasal cannula or ended with room air, mortality rate, and the principal safety criterion was presence of bleeding. Results: Of 160 subjects, 63.8% were male and 45.6% were aged 45-59 years old. Obesity was the most common comorbidity at 45.6% Among all subjects, 9.4% experienced bleeding, with hematuria being the most frequent type at 66.7%. All subjects released HFNC, and no deaths were reported. Conclusions: It can be concluded that administration of therapeutic doses of heparin in patients with severe COVID-19 had a low risk of bleeding and no patients were reported to have died. However, further investigation is needed to determine the long-term effects of therapeutic doses of anticoagulants.
- 29 July 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (07) , 1002-1009
Open AccessEfficacy of therapeutic-dose heparin for severe COVID-19 patients at COVID-19 Emergency Hospital Jakarta
Introduction: Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality. For optimal thromboprophylaxis treatment for hospitalized patients, especially those with severe COVID-19 symptoms, it is still unclear whether to use full- or therapeutic-dose versus prophylactic-dose anticoagulation therapy. The study aim was to evaluate the efficacy and safety of unfractionated heparin (UFH) for thromboprophylaxis in severe degree of COVID-19. Methodology: In this cross-sectional study, the medical records of 160 COVID-19 patients at the COVID-19 Emergency Hospital Wisma Atlet, Jakarta, from March to August 2021, were collected. The predetermined inclusion criteria for patients were severe COVID-19 infection; age > 18 years; positive D-dimer level > 400 ng/mL; high-flow nasal cannula (HFNC) oxygenation; IMPROVE bleeding risk score < 7; and willingness to participate in the study. The primary outcome was activated partial thromboplastin time (APTT) target achievement, oxygenation changed to nasal cannula or ended with room air, mortality rate, and the principal safety criterion was presence of bleeding. Results: Of 160 subjects, 63.8% were male and 45.6% were aged 45-59 years old. Obesity was the most common comorbidity at 45.6% Among all subjects, 9.4% experienced bleeding, with hematuria being the most frequent type at 66.7%. All subjects released HFNC, and no deaths were reported. Conclusions: It can be concluded that administration of therapeutic doses of heparin in patients with severe COVID-19 had a low risk of bleeding and no patients were reported to have died. However, further investigation is needed to determine the long-term effects of therapeutic doses of anticoagulants.
- Open Access
- 1 June 2024
- Published by Institute of Advanced Engineering and Science in International Journal of Public Health Science (IJPHS)
- Vol. 13 (2) , 775-782
Adverse events following immunization of mRNA-1273 (Moderna) booster vaccine in clerkship students
Two-dose primary vaccine administration was the best strategy to reduce the prevalence and severity of COVID-19. Improved immunity and antibody response to the new variant virus by administering a booster vaccine is needed. Health workers are the main priority for administering the mRNA-1273 (Moderna) booster vaccination in Indonesia. This vaccine has high effectiveness, and safety, however, data and evaluation of adverse events following immunization (AEFI) is required. This study aimed to determine the AEFIs of mRNA-1273 booster vaccination in clinical clerkship students as an early adult age group. The research design was a repeated cross-sectional study using purposive sampling technique. There were 214 subjects who met the requirements. Subject filled out an online questionnaire containing evaluation of AEFIs. The most local AEFIs symptoms were pain at the injection site (79.0%), while the common systemic symptoms were headache, drowsiness, weakness, and fever (37.4%; 26.2%; 9.8%; 9.3%). Most AEFIs were felt within 30 minutes to three days. No respondents required hospitalization, experienced anaphylactic shock, became disabled, or died. The AEFIs did not have a significant relationship with gender, history of allergies, co-morbidities, or history of COVID-19. This information is used as a preventive or educational effort to support implementation vaccine in Indonesia.
- 1 June 2024
- Published by Institute of Advanced Engineering and Science in International Journal of Public Health Science (IJPHS)
- Vol. 13 (2) , 775-782
Open AccessAdverse events following immunization of mRNA-1273 (Moderna) booster vaccine in clerkship students
Two-dose primary vaccine administration was the best strategy to reduce the prevalence and severity of COVID-19. Improved immunity and antibody response to the new variant virus by administering a booster vaccine is needed. Health workers are the main priority for administering the mRNA-1273 (Moderna) booster vaccination in Indonesia. This vaccine has high effectiveness, and safety, however, data and evaluation of adverse events following immunization (AEFI) is required. This study aimed to determine the AEFIs of mRNA-1273 booster vaccination in clinical clerkship students as an early adult age group. The research design was a repeated cross-sectional study using purposive sampling technique. There were 214 subjects who met the requirements. Subject filled out an online questionnaire containing evaluation of AEFIs. The most local AEFIs symptoms were pain at the injection site (79.0%), while the common systemic symptoms were headache, drowsiness, weakness, and fever (37.4%; 26.2%; 9.8%; 9.3%). Most AEFIs were felt within 30 minutes to three days. No respondents required hospitalization, experienced anaphylactic shock, became disabled, or died. The AEFIs did not have a significant relationship with gender, history of allergies, co-morbidities, or history of COVID-19. This information is used as a preventive or educational effort to support implementation vaccine in Indonesia.
- Open Access
- 1 November 2023
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 20 (6) , em549
Obesity, dyslipidemia, and diabetes mellitus as risk factors in cholelithiasis
Objectives: Cholelithiasis or gallstones has many risk factors, such as age, sex, obesity, dyslipidemia, and diabetes mellitus (DM). Studies in developing country shown that obesity, dyslipidemia, and DM occurred in 55.0%, 76.0%, and 17.7% of adults with cholelithiasis, respectively. The aim of this study is to know the proportion of cholelithiasis risk factors. Materials & methods: This retrospective study using descriptive cross sectional design performed in one of the largest referral hospital in Jakarta Indonesia. Demographic data, and laboratory examination were collected from medical record. Patients presented with cholelithiasis from the abdominal ultrasonography was enrolled into study. Results: 93 subjects were selected through consecutive sampling, where in 65.8% were female and 77.5% age>40 years. The majority was obese (47.3%) and the obesity grade I was most prevalent. Dyslipidemia was found in 19.3% subjects with proportion of high total cholesterol was 54.5%, high LDL 90.9%, high triglycerides 27.3%, and low HDL 18.2%. DM was found in 15.0% subjects. Random blood glucose had higher proportion, accounting 57.2% with mean 140.67± 89.69 mg/dl. Female and age>40 years had more proportion in cholelithiasis patients. Conclusions: Proportion of cholelithiasis with obesity 47.3%, dyslipidemia 19.3%, and diabetes 15.0%. However, the proportion of obesity, dyslipidemia and diabetes in this study was lower than other studies in Asia or developing countries. Patients with obesity grade I, high LDL and RBG>40 mg/dl should be aware to have cholelithiasis.
- 1 November 2023
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 20 (6) , em549
Open AccessObesity, dyslipidemia, and diabetes mellitus as risk factors in cholelithiasis
Objectives: Cholelithiasis or gallstones has many risk factors, such as age, sex, obesity, dyslipidemia, and diabetes mellitus (DM). Studies in developing country shown that obesity, dyslipidemia, and DM occurred in 55.0%, 76.0%, and 17.7% of adults with cholelithiasis, respectively. The aim of this study is to know the proportion of cholelithiasis risk factors. Materials & methods: This retrospective study using descriptive cross sectional design performed in one of the largest referral hospital in Jakarta Indonesia. Demographic data, and laboratory examination were collected from medical record. Patients presented with cholelithiasis from the abdominal ultrasonography was enrolled into study. Results: 93 subjects were selected through consecutive sampling, where in 65.8% were female and 77.5% age>40 years. The majority was obese (47.3%) and the obesity grade I was most prevalent. Dyslipidemia was found in 19.3% subjects with proportion of high total cholesterol was 54.5%, high LDL 90.9%, high triglycerides 27.3%, and low HDL 18.2%. DM was found in 15.0% subjects. Random blood glucose had higher proportion, accounting 57.2% with mean 140.67± 89.69 mg/dl. Female and age>40 years had more proportion in cholelithiasis patients. Conclusions: Proportion of cholelithiasis with obesity 47.3%, dyslipidemia 19.3%, and diabetes 15.0%. However, the proportion of obesity, dyslipidemia and diabetes in this study was lower than other studies in Asia or developing countries. Patients with obesity grade I, high LDL and RBG>40 mg/dl should be aware to have cholelithiasis.